

Prior Authorization Request Form for Long-Acting Opioid Analgesics

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720
OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

OKT	ioi autilolization may t	e completed at intps://w	ww.coverniyine	us.com/mam/pr	or-authorization-torins/		
☐New request	Renewal request # of pages: Prescriber name:						
Name of office contact:			Specialty:				
Contact's phone number:			NPI:		State license #:		
LTC facility contact/phone:			Street address:				
Member name:			City/state/zip:				
Member ID#:		DOB:	Phone:		Fax:		
CLINICAL INFORMATION							
Drug requested:			Strength:	Form	ulation (capsule, tablet, etc.):		
Directions:				Weig	nt (if <21 years of age):		
Quantity per fill: to last			days	Requested durat	Requested duration:		
Diagnosis (submit documentation):				Dx code (<u>required</u>):			
Pennsylvania law requires prescribers to query the <u>PA PDMP</u> each time a patient is prescribed an opioid drug product or benzodiazepine.							
 Naloxone is available at Pennsylvania pharmacies via standing order from the Secretary of the Department of Health. Pennsylvania Medical Assistance beneficiaries may obtain naloxone <u>free-of-charge</u> through their prescription drug benefit. 							
Complete all sections that apply to the member and this request. Check all that apply and submit documentation for each item.							
INITIAL requests							
1. For a non-preferred Analgesic, Opioid Long-Acting (See the Preferred Drug List for the list of preferred and non-preferred Analgesics, Opioid Long-Acting at: https://papdl.com/preferred-drug-list): [For a non-preferred product containing buprenorphine :							
Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting containing <u>buprenorphine</u> For a non-preferred product containing <u>tramadol</u> :							
Tried and failed or has a contraining <u>uranidod</u> . Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting containing <u>tramadol</u> For all other non-preferred Analgesics, Opioid Long-Acting:							
☐Tried date):	Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting (medication, start and end date):						
¹ 2. For a membe	r with a concurrent presci	iption for a buprenorphine	agent indicated for	or the treatment o	f opioid use disorder (OUD) OR		

	Vivitrol (naltrexone extended-release suspension for injection):
	■ Both prescriptions are prescribed by the same prescriber Prescriptions are prescribed by different prescribers and all prescribers are aware of the other prescription(s)
	Not applicable –member is not taking a buprenorphine agent indicated for the treatment of OUD or Vivitrol
3.	For <u>all</u> Analgesics, Opioid Long-Acting:
	Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome
	Is receiving palliative care or hospice services
	Has documentation of pain that is all of the following:
	Caused by a medical condition:
	□Not migraine in type
	Severe
	Tried and failed or has a contraindication or an intolerance to non-opioid analgesics appropriate for the member's condition:
	☐ acetaminophen:
	gabapentinoids (e.g., gabapentin, pregabalin [Lyrica]):
	☐ SAIDs (e.g., ibuprofen, naproxen, meloxicam, etc.):
	☐ tricyclic antidepressants (e.g., amitriptyline, nortriptyline, etc.):
	other (specify):
	Has documentation of a trial of short-acting opioids:
	Is opioid-tolerant (for adults, is defined as taking at least morphine 60 mg/day, transdermal fentanyl 25 mcg/hour, oxycodone 30 mg/day, oral
	hydromorphone 8 mg/day, or an equianalgesic dose of another opioid for one week or longer)
	Was assessed by the prescriber for the potential risk of opioid misuse or opioid use disorder
	Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abuse, including specific testing for
	oxycodone, fentanyl, buprenorphine, and tramadol, that is consistent with prescribed controlled substances
4.	For a member with a concurrent prescription for a benzodiazepine:
	☐ The benzodiazepine is being tapered
	☐ The opioid is being tapered
	Concomitant use of the benzodiazepine and opioid is medically necessary
	Not applicable – member is not taking a benzodiazepine
	RENEWAL requests
1.	For all Analgesics, Opioid Long-Acting:
	Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome
	☐ Is receiving palliative care or hospice services
	Experienced an improvement in pain control and/or level of functioning while on the requested medication
	Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abuse, including specific testing for
	oxycodone, fentanyl, buprenorphine, and tramadol, at least every 12 months that is consistent with prescribed controlled substances
2.	For a member with a concurrent prescription for a benzodiazepine:
	The benzodiazepine is being tapered
	The opioid is being tapered
	Concomitant use of the benzodiazepine and opioid is medically necessary
	Not applicable – member is not taking a benzodiazepine
	ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 844-205-3386				
Prescriber Signature:	Date:			

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)